-With the new expansion, Ritedose's total BFS capacity will
exceed 2.6 billion units—solidifying Ritedose as the largest BFS
manufacturer in the United
States
-Ritedose has co-developed and commercialized more
than 80% of new products introduced in BFS in the past
decade
COLUMBIA, S.C., June 20,
2024 /PRNewswire/ -- The Ritedose Corporation
(Ritedose), the leading contract development and manufacturing
organization (CDMO) specializing in sterile Blow Fill Seal (BFS)
production, announces a significant expansion of its production
capabilities to meet the demand for ophthalmic and respiratory
medications.
Investment in expansions reflect our
commitment to providing reliable, quality unit dose solutions for
our customers.
Ritedose has expanded its sterile Blow-Fill-Seal (BFS)
capabilities, and the new equipment is expected to begin production
in August of this year. The addition of another 180-million-unit
dose capacity for ophthalmic and respiratory medications
underscores the company's commitment to meeting the increasing
demand from cutting edge ophthalmic and respiratory drug developers
for high-quality, sterile unit dose solutions.
"This expansion marks a pivotal moment in our company's
history," said CEO of Ritedose Jody Chastain. "We're passionately
dedicated to advancing the health and well-being of patients across
the United States—it's why we come to work every single day. We are
perfectly positioned to support our partners and deliver quality
medications, and both they and our patients count on us to be steps
ahead in capacity, capabilities and without a doubt, quality. It's
our forward-looking strategy and commitment that has allowed us to
maintain a 100% customer retention rate over the past 25
years."
The new capacity will be integrated into Ritedose's
state-of-the-art manufacturing facility in Columbia, SC, which adheres to the highest
standards of quality and compliance. The facility is equipped with
cutting-edge technology and staffed by a team of highly skilled
professionals committed to excellence in sterile manufacturing.
With an emphasis on providing an exceptional workplace for its
employees, Ritedose remains a leading employer in the Midlands, employing over 600 people.
This strategic expansion enhances the Company's ability to serve
its customers more efficiently and ensure a consistent supply of
critical medications. Increasing capacity also allows Ritedose to
respond to a rising need for ophthalmic and respiratory treatments
due to an increasing prevalence of respiratory diseases and an
aging population requiring advanced eye care solutions.
"Ritedose has co-developed and commercialized more than 80% of
new products introduced in a BFS dosage form for the past 10 years.
This track record of successful partnerships highlights the
Company's role as a key innovator in the BFS sector and a trusted
collaborator for pharmaceutical companies. To remain laser focused
on growing our capacity, innovation and specialty in BFS, we are
making a strategic decision to pivot the necessary resources away
from our 503B Outsourcing
Division—concentrating all resources to FDA approved drug
products," Chastain continued.
Ritedose's continued investment in capacity expansion and
technological innovation reflects its unwavering commitment to its
mission of providing reliable, high-quality unit dose solutions for
the pharmaceutical industry.
About The Ritedose Corporation
Ritedose is the largest
sterile contract development manufacturing organization (CDMO) in
the US specializing in sterile Blow Fill Seal (BFS) technology that
ensures sterile, consistent, and safe unit dose delivery. The
company's process guides the development of molecules from clinical
trials to commercialization of branded and generic inhalation and
ophthalmic medications and compounding single-unit dose syringes.
With a focus on quality, innovation, and customer satisfaction,
Ritedose partners with leading pharmaceutical companies to deliver
safe, effective, and reliable medications that improve patient
outcomes. For more information about Ritedose and its services:
visit Ritedose.com
Media Contact:
Alex Keown
Inspire Agency on Behalf of Ritedose
630.346.5141
akeown@inspire-agency.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ritedose-the-leading-pharmaceutical-manufacturer-cdmo-specializing-in-sterile-blow-fill-seal-expands-its-bfs-capacity-to-meet-the-growing-demand-for-ophthalmic-and-respiratory-medications-302177567.html
SOURCE Ritedose